Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Appili Therapeutics Inc.
  6. News
  7. Summary
    APLI   CA03783R1073

APPILI THERAPEUTICS INC.

(APLI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Appili Therapeutics : Closes Public Offering of Near $7 Million

10/14/2021 | 10:27am EST


ę MT Newswires 2021
All news about APPILI THERAPEUTICS INC.
11/22Appili Therapeutics Announces Positive One Year Challenge Results from Preclinical Stud..
AQ
11/19Appili Details "Positive" One Year Challenge Results from Preclinical Study Evaluating ..
MT
11/19Appili Therapeutics Announces Positive One Year Challenge Results from Preclinical Stud..
BU
11/19Appili Therapeutics Inc. Announces Positive One Year Challenge Results from Preclinical..
CI
11/19Appili Therapeutics Inc. Announces Resignation of Josef Vejvoda from the Board of Direc..
CI
11/15Appili Therapeutics Provides Update on Phase 3 PRESECO Clinical Trial Evaluating Avigan..
AQ
11/12Appili Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months..
CI
11/12Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fis..
BU
11/12Appili Therapeutics Inc. Announces Executive Changes
CI
11/12IIROC Trade Resumption - APLI
AQ
More news
Financials
Sales 2022 - - -
Net income 2022 -27,8 M -22,0 M -22,0 M
Net Debt 2022 - - -
P/E ratio 2022 -0,36x
Yield 2022 -
Capitalization 9,26 M 7,33 M 7,32 M
Capi. / Sales 2022 -
Capi. / Sales 2023 0,97x
Nbr of Employees 15
Free-Float 78,8%
Chart APPILI THERAPEUTICS INC.
Duration : Period :
Appili Therapeutics Inc. Technical Analysis Chart | APLI | CA03783R1073 | MarketScreener
Technical analysis trends APPILI THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Last Close Price 0,13 CAD
Average target price 0,72 CAD
Spread / Average Target 451%
EPS Revisions
Managers and Directors
Armand L. Balboni Chief Executive Officer & Director
Kenneth G. Howling Chief Financial Officer
Ian C. Mortimer Chairman
Yoav Golan Chief Medical Officer
Theresa Matkovits Independent Director
Sector and Competitors
1st jan.Capi. (M$)
APPILI THERAPEUTICS INC.-88.11%7
GILEAD SCIENCES, INC.19.55%87 368
BIONTECH SE243.27%73 106
REGENERON PHARMACEUTICALS31.46%66 402
WUXI APPTEC CO., LTD.24.26%63 075
VERTEX PHARMACEUTICALS-13.17%52 178